Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2006-09-19
2010-06-29
Rawlings, Stephen L (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S138100, C424S155100, C424S174100, C424S181100, C424S183100, C530S350000, C530S387300, C530S387700, C530S388800, C530S389700, C530S391300, C530S391700
Reexamination Certificate
active
07744878
ABSTRACT:
Provided herein is disclosure about the development and characterization of an antibody (mPA7) which binds to antigen CD46 which is present on a variety of human cancers from ovary, breast, lung, prostate, colon, kidney, and pancreas. Methods of diagnosing and treating various cancers by using antibodies such as mPA7 directed against this antigen are also disclosed.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5514787 (1996-05-01), Atkinson
patent: 5552381 (1996-09-01), Atkinson
patent: 5665570 (1997-09-01), Yamagata et al.
patent: 5677425 (1997-10-01), Bodmer et al.
patent: 5703046 (1997-12-01), Atkinson
patent: 5760185 (1998-06-01), Kimachi et al.
patent: 5773247 (1998-06-01), Maeda et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5846715 (1998-12-01), Purcell et al.
patent: 5866692 (1999-02-01), Shitara et al.
patent: 5929212 (1999-07-01), Jolliffe et al.
patent: 5932225 (1999-08-01), Wallach et al.
patent: 5997867 (1999-12-01), Waldmann et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6086876 (2000-07-01), Karp et al.
patent: 6110724 (2000-08-01), Nakagomi et al.
patent: 6117653 (2000-09-01), Thoma
patent: 6180377 (2001-01-01), Morgan et al.
patent: 6210671 (2001-04-01), Co
patent: 6218520 (2001-04-01), Atkinson
patent: 6221644 (2001-04-01), Berka et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6350861 (2002-02-01), Co et al.
patent: 6441163 (2002-08-01), Chari et al.
patent: 7148038 (2006-12-01), Mather
patent: 2002/0115065 (2002-08-01), Logtenberg et al.
patent: 2003/0108966 (2003-06-01), Mather
patent: 2003/0129677 (2003-07-01), Martens et al.
patent: 2004/0045045 (2004-03-01), Mather et al.
patent: 2005/0037439 (2005-02-01), Bourner et al.
patent: 2008/0108794 (2008-05-01), Goldenberg et al.
patent: 0 519 596 (1992-12-01), None
patent: WO-01/27160 (2001-04-01), None
patent: WO-01/88537 (2001-11-01), None
patent: WO-02/18948 (2002-03-01), None
patent: WO-02/18948 (2002-03-01), None
patent: WO-03/032814 (2003-04-01), None
patent: WO-03/032814 (2003-04-01), None
Reimer et al. (J. Immunol. 2004; 174: 394-401).
Jurianz et al. (Immunopharmacol. 1999; 42: 209-218).
Fishelson et al. (Mol. Immunol. 2003; 40: 109-123).
Wojnicz et al. (Postepy. Hig. Med. Dosw. 2002; 56 (5): 603-616).
Pollard et al. (Gene. 1998; 212: 39-47).
Nomura et al. (Immunogenetics. 1999 50: 245-254).
Hara et al. (Scand. J. Immunol. 1995; 42: 581-590).
Purcell et al. (Immunogenetics. 1991; 33: 335-344).
Seya et al. (Int. J. Biochem. Cell Biol. 1999; 31: 1255-1260).
Caldas et al. (Mol. Immunol. May 2003; 39 (15): 941-952).
Stancoviski et al. (Proceedings of the National Academy of Science USA. 1991; 88: 8691-8695).
Jiang et al. (J. Biol. Chem. Feb. 11, 2005; 280 (6): 4656-4662).
Riemer et al. (Mol. Immunol. 2005; 42: 1121-1124).
Henry et al. (Cancer Res. Nov. 1, 2004; 64: 7995-8001).
McDevitt et al. (Cancer Res. Nov. 1, 2000; 60: 6095-6100).
Ollert et al. (J. Immunol. 1995; 155: 4955-4962).
Gorter et al. (Lab. Investig. 1996; 74: 1039-1049).
Maenpaa et al. (Am. J. Pathol. 1996; 148: 1139-1152).
Dillman (Curr. Pharmaceut. Biotechnol. 2001; 2: 293-300).
Weiner et al. (Semin. Oncol. 1999; 26: 43-51).
Loberg et al. (Urology. Dec. 2005; 66 (6): 1321-1326).
Goslings et al. (Investig. Ophthalmol. Vis. Sci. 1996; 37: 1884-1891).
Gelderman et al. (Mol. Immunol. 2003; 40: 13-23).
Niehans et al. (Am. J. Pathol. 1996; 149: 129-142).
Bodey et al. (Anticancer Res. 2000; 20: 2665-2676).
Lollini et al. (Curr. Cancer Drug Targets. May 2005; 5 (3): 221-228).
Lollini et al. (Trends Immunol. Feb. 2003; 24 (2): 62-66).
Slinghuff et al. (Cancer Immunol. Immunother. Mar. 2000; 48 (12): 661-672).
Madjd et al. (Cancer Immunol. Immunother. 2005; 54: 149-156).
Rushmere et al. (Int. J. Cancer. Mar. 1, 2004; 108 (6): 930-936).
Blok et al. (Lab. Invest. Mar. 2000; 80 (3): 335-344).
Gura (Science. 1997; 278: 1041-1042).
Dennis (Nature. Aug.7, 2006; 442: 739-741).
Kelland (Eur. J. Cancer. Apr. 2004; 40 (6): 827-836).
Schuh (Toxicologic Pathology. 2004; 32 (Suppl. 1): 53-66).
Suggitt et al. (Clin. Cancer Res. Feb. 1, 2005; 11: 971-981).
Greenspan et al. (Nature Biotechnology. 1999; 7: 936-937).
Mariuzza et al. (Annu. Rev. Biophys. Biophys. Chem. 1987; 16: 139-159).
Gussow et al. (Methods in Enzymology. 1991; 203: 99-121).
Giusti et al. (Proc. Natl. Acad. Sci. USA. May 1987; 84 (9): 2926-2930).
Chien et al. (Proc. Natl. Acad. Sci. USA. Jul. 1989; 86 (14): 5532-5536).
Weng et al. (Blood. Sep. 1, 2001; 98 (5): 1352-1357).
Zell et al. (Clin. Exp. Immunol. Dec. 2007; 150 (3): 576-584).
Liszewski et al. (Curr. Top. Microbiol. Immunol. 1992; 178: 45-60).
Adams, E.M. et al. (Nov. 1, 1991). “Contribution of the Repeating Domains of Membrane Cofactor Protein (CD46) of the Complement System to Ligand Binding and Cofactor Activity,”The Journal of Immunology147(9):3005-3011.
Allen, B.J. et al. (2001). “In Vitro and Preclinical Targeted Alpha Therapy for Melanoma, Breast, Prostate and Colorectal Cancers,”Crit. Rev. Oncol. Hmatol.39:139-146.
Andrew, S.M. et al. (1990). “Tumor Localizations by Combinations of Monoclonal Antibodies in a New Human Colon Carcinoma Cell Line (LIM1899),”Cancer Res.50: 5225-30.
Aruffo, A. et al. (1987). “Molecular Cloning of a CD28 cDNA by High-Efficiency COS Cell Expression System,”Proc. Natl. Acad. Sci. USA 84:8573-8577.
Azuma, A. et al. (1995). “Augmented Lung Adenocarcinoma Cytotoxicity by the Combination of a Genetically Modified Anti-Lewis Y Antibody and Antibodies to Complement Regulatory Proteins,”Scand. J. Immunol. 42: 202-208.
Ballard, L. et al. (1987). “A Polymorphism of the Complement Regulatory Protein MCP (Membrane Cofactor Protein or gp45-70),”J. Immunol. 138(11):3850-3855.
Bjorge, L. et al. (1996). “Characterisation of the Complement-Regulatory Proteins Decay-Accelerating Factor (DAF, CD55) and Membrane Cofactor Protein (MCP, CD46) on a Human Colonic Adenocarcinomic Cell Line,”Cancer Immunol. Immunother.42:185-192.
Bjorge, L. et al. (1997). “Complement-Regulatory Proteins in Ovarian Malignancies,”Int. J. Cancer70:14-25.
Blok, V.T. et al. (2000). “A Possible Role of CD46 for the Protection In Vivo of Human Renal Tumor Cells from Complement-Mediated Damage,”Lab. Invest.80(3):335-44.
Blom, D-J. et al. (1997). “Lack of Effect of Different Cytokines on Expression of Membrane-Bound Regulators of Complement Activity on Human Uveal Melanoma Cells,”J Interferon Cytokine Res.17(11):695-700.
Brown, B.A. et al. (1987). “Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody,”Cancer Research47:3577-3583.
Buchholz, C.J. et al. (Aug. 29, 1997). “Mapping of the Primary Binding Site of Measles Virus to its Receptor CD46,”Journal of Biological Chemistry272(35):22072-22079.
Cho, S-W. et al. (1991). “Characterization of Three Monoclonal Antibodies to Membrane Co-Factor Protein (MCP) of the Complement System and Quantification of MCP by Radioassay,”Clin. Exp. Immunol. 83:257-261.
Cole, J.L. et al. (1985). “Identification of an Additional Class of C3-Binding Membrane Proteins of Human Peripheral Blood Leukocytes and Cell Lines,”Proc. Natl. Acad. Sci. USA 82:859-869.
Daugherty, B.L. et al. (1991). “Polymerase Chain Reaction Facilitates the Cloning, CDR-Grafting, and Rapid Expression of a Munine Monoclonal Antibody Directed Against the CD 18 Component of Leukocyte Integrins,”Nucleic Acids Research19(9):2471-2476.
Dillman, R.O. et al. (1988). “Superiority of an Acid-Labile Daunorubicin—Monoclonal Antibody Immonoconjugate Compared to Free Drug,”Cancer Research48:6097-6102.
Donin, N. et al. (2003). “Complement Resistance of Human Carcinoma Cells Depends on Membrane Regulatory Proteins, Protein Kinases and Sialic Acid,”Clin. Exp. Immunol.131:254-263.
Durrant, L.G. et al. (Jul. 2001). “Immunization Against Tumor Cell Surface Complement-Regulatory Proteins,”Current Opinion in Investigational Drugs2(7):959-966.
Auerbach Jeffrey I.
Edell Shapiro & Finnan LLC
Raven biotechnologies, inc.
Rawlings Stephen L
LandOfFree
Antibodies that bind to cancer-associated antigen CD46 and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies that bind to cancer-associated antigen CD46 and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies that bind to cancer-associated antigen CD46 and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4197620